Premium
Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE ‐023 study
Author(s) -
Mateos MariaVictoria,
Orlowski Robert Z.,
Ocio Enrique M.,
RodríguezOtero Paula,
Reece Donna,
Moreau Philippe,
Munshi Nikhil,
Avigan David E.,
Siegel David S.,
Ghori Razi,
Farooqui Mohammed Z. H.,
Marinello Patricia,
San-Miguel Jesus
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15946
Subject(s) - lenalidomide , dexamethasone , multiple myeloma , medicine , pembrolizumab , refractory (planetary science) , oncology , cancer , materials science , immunotherapy , composite material